ITEOS THERAPEUTICS INC (ITOS)

Company Profile

iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. The company is headquartered in Watertown, Massachusetts and currently employs 125 full-time employees. The company went IPO on 2020-07-24. The firm is focused on the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. The Company’s pipeline includes two clinical-stage programs targeting novel, validated immuno-oncology pathways. Its lead antibody product candidate, EOS-448, also known as GSK4428859A, is an antagonist of T-cell immunoreceptor with lg and ITIM domains, an immune checkpoint with multiple mechanisms of action. The firm is also advancing inupadenant, a next generation adenosine A2A receptor antagonist tailored to overcome the specific adenosine-mediated immunosuppression. The company is investigating inupadenant in an open-label multi-arm Phase I/IIa clinical trial in adult cancer patients with advanced solid tumors.

Company Info

ITEOS THERAPEUTICS INC

321 Arsenal Street, Bldg 312, Floor 3, Suite 301

Watertown MASSACHUSETTS 02142

P: 18572044583

CEO: Michel Detheux

Employees: 125

Website: https://www.iteostherapeutics.com/